Meeting
2021 ASCO Annual Meeting
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
Presenter
Alison M. Schram, MD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT04526106
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4165)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4165
Abstract #
TPS4165
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
Speaker: James J. Harding, MD
Videos & Slides
2024 ASCO Annual Meeting
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
Speaker: Johan Erik Wallin, PhD, MSc, MPharm
Videos & Slides
2024 ASCO Annual Meeting
Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.
Speaker: Brian Andrew Van Tine, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort.
Speaker: Xiaoyu Li, MD